Cipla, Biocon, Lupin, Other Pharma Stocks Under Pressure Post Trump's 100% Tariff
Nifty Pharma index declined 2.67% intraday on Friday after US President Donald Trump announced a 100% tariff on the sector with an exception for companies that have manufacturing capacity in the United States.
Specific details are yet to be shared, but preliminary details show that the US tariffs mainly target branded and patented drugs. So, consequently, it is unclear whether complex generics and specialty drugs from India could also face scrutiny.
However, stocks of Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr Reddy's Laboratories Ltd., Lupin Ltd., and Biocon Ltd. still declined on Friday.
Sun Pharmaceutical Industries Ltd. declined nearly 5% as the company is likely to see some impact until it announces its US capex plans. Cipla Ltd. declined 2.29%, Biocon Ltd. declined 2.78%, Dr Reddy's Lab declined 2.27% intraday to trade at Rs 1,246.20 apiece, and Lupin Ltd. declined 2.47% intraday to trade at Rs 1,915 apiece.

Notably, the US tariffs mainly target branded and patented drugs, a market dominated by multinational companies like Pfizer Inc. and Novo Nordisk Inc. Sun Pharmaceutical Industries Ltd. and Biocon Ltd. are also key branded players in the US.
Bengaluru-based Biocon, through its wholly owned subsidiary Biocon Generics Inc., commissioned its US manufacturing facility earlier this month in Cranbury, New Jersey. Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over $30 million to establish a state-of-the-art plant with an annual production capacity of two billion tablets.
Meanwhile Sun Pharma too may have some impact until it announces its US capex plans. It exports specialty drugs like ILUMYA, CEQUA, WINLEVI and ODOMZO. This category contributes 19% to overall revenue.
In FY25, Global Specialty sales rose by 17.1%, reaching $1,216 million. Additionally, Specialty R&D accounted for 36% of the company's total R&D spend in Q4FY25.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.